Nice summary. This is my understanding and most on this board. It is mind boggling to me that with higher rates in our future that NRZ has been trending down, instead of up. Hopefully, this starts turning around soon. Personally, my portfolio is already heavily weighted in NRZ at lower prices, so I cannot justify buying more at this time. Nierenberg is a smart guy and I am sure he will continue to look for opportunities to make money. NRZ is somewhat unique, and is not hemmed in by anything. This is also one of the reasons though PPS is as low it is. As NRZ becomes a more mature company in the eyes of investors and analysts, it should trade more in the range that it deserves. This was also echoed in the last conference call. GL!
High response rate and progression free survival with PEGylated recombinant human hyaluronidase added to Nab-Paclitaxel/Gemcitabine in stage IV previously untreated pancreatic cancer patients with high-HA tumors: Interim results of a randomized Phase 2 study
Not sure if there are other abstracts. GLTA!
Short term market actions has no impact on SYN and other biotechs not looking to access the markets for new cash. The $200 million shelf registration is standard operating procedure and not indicative as to when SYN will have another secondary, if at all depending upon partnering, etc. Sorry shorts, it is an administrative move to satisfy SEC regulations and to be ready when and if money is needed. Dollar amount also does not indicate what a next secondary would be, since smaller secondaries are of course possible.
I loved your post for a good chuckle. What do you mean by "these type of stocks RARELY sell much above book value?" What type of stock do you categorize SNR as that you made this comment? So you think it is typical that a REIT sells around BV? I think it is the other way around.
I do not recall a REIT buying back stock that I can think of. They would have to be selling properties to generate meaningful cash for a buyback, or take out debt. SNR is in growth mode, so it would be counterintuitive for management to be buying back shares. SNR is already fairly levered, so the issuance of shares was a good choice. When they have more history as a company, better financing I am sure will be possible than today.
I do not like where SNR is trading, but that is not indicative of their performance. Institutional investors are significantly invested in SNR and continue to buy, which gives me a level of comfort that PPS is bottoming out and set to move up in the future. Recently, there was an article in the WSJ that talked about excess capacity in this space which may be weighing on the PPS. There are so many factors variables, it is hard to put ones finger on why SNR PPS has declined. However, I do not think it has been performance. In the meantime, I'll collect my dividend and wait for Wes and company to build value as he has done for me and other long term investors in NCT and its spin offs.
FBR & Co. 2nd Annual Healthcare Conference
Wednesday, September 9, 2015
Jeffrey Riley, CEO, was invited to participate in FBR's One-on-One Healthcare Conference in Boston, MA.
SYN can potentially press release information the day of the conference, any time before the
If he wants to really clue us in, he should buy shares on the open market along with others in senior management and the board. That's a sign.
Big boost in ownership in Q2. Some see a bargain. Cooperman bought 2.6M shares in Q2 nearly doubling his holdings for a total of 5.4 million. Vanguard bought a big chunk, too.
Increased Positions 101 22,683,137
Decreased Positions 59 3,947,754
Held Positions 21 43,612,756
Total Institutional Shares 181 70,243,647
I understand that since the data reported on the NASDAQ site is reported through bots, there can be some doubling of the data, in some cases. Taking this into consideration, institutional ownership still moved up a lot.
Increased Positions 177 81,691,953
Decreased Positions 54 3,582,003
Held Positions 27 82,849,257
Total Institutional Shares258 168,123,213
New Positions 65 19,973,122
Sold Out Positions 16 1,239,588
NRZ is off its high, but at least institutions have recognized (and validated) that there is a lot of value in owning NRZ,. Good luck to all longs!
This speculation on Rob's part is garbage and self serving, if you ask me. His head is getting too big, IMO.
This is contrary to the 8K Exhibit IV Section 3.1 of the Amendment to the Clinical Trial Agreement, so I do not have a good theory as to why the difference. I also am not sure when Riley's prepared remarks were written, but I would go with what is in the 8K.
The call was as expected for me. I was not expecting Trimesta trials results, or partner news, since it is too soon. Trial results cannot come out before Dr. V publication and SYN just received the data and the independent evaluation just begun. This is what Riley was able to say:
"The MS drug cognition that current phase, that’s ongoing, is funded by both UCLA and Synthetic Biologics. And we’re looking forward to moving that thing forward. I mean at the end of the day, we did issue some data here a few weeks ago that we did talk to UCLA and basically renegotiated set of terms that were more beneficial to both parties. We got some intellectual property, they got better economics and that has given us the ability to move the MRI program and the data forward.
Keep in mind that both the MRI data as well as the relapse remitting data will also be analyzed by the independent third party, I mean, that’s typical in the industry. And it’s really important to note that because it does take time for us to have a third party, look at the data, provide their analysis back for potential partnering with various folks out there."
In regards to the shelf registration, this is common business practice.
Nothing has changed except that we have some over-zealous posters that have talked themselves into thinking we would hear news on this call. Good luck to all longs!
That is where management wants the dividend yield to move to. Expected PPS is based upon current annualized dividend of $1.80. Great call today. GLTA longs!
Bodes well for the future. GLTA longs!
You should sell your shares. Only own shares in companies that have management that you trust. Hopefully, this is your last post. The call met my expectations. I, along with others have said not to expect news on Trimesta on this call.